Chinook Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Chinook Therapeutics (Nasdaq: KDNY) has announced its participation in the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023, at 11:15 am EST in San Francisco, CA. The company will present its advancements in developing precision medicines for kidney diseases.
The presentation will be accessible via an audio webcast, with an archived version available for 30 days on the company’s website. Chinook is focused on clinical-stage therapies for severe kidney disorders, including its lead program, atrasentan, for IgA nephropathy.
Positive
- None.
Negative
- None.
News Market Reaction – KDNY
In the trading session that priced this news, KDNY gained 0.79%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SEATTLE, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that Chinook management will present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 11, 2023 at 11:15 am EST, and participate in 1x1 meetings.
To access the audio webcast and subsequent archived recording of this and other company presentations, please visit the Investors section of Chinook’s website. The archived audio webcast will remain available for replay on Chinook’s website for 30 days.
About Chinook Therapeutics, Inc.
Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing precision medicines for kidney diseases. Chinook’s product candidates are being investigated in rare, severe chronic kidney disorders with opportunities for well-defined clinical pathways. Chinook’s lead program is atrasentan, a phase 3 endothelin receptor antagonist for the treatment of IgA nephropathy and proteinuric glomerular diseases. BION-1301, an anti-APRIL monoclonal antibody, is being evaluated in a phase 1/2 trial for IgA nephropathy. CHK-336, an oral small molecule LDHA inhibitor for the treatment of hyperoxalurias, is being evaluated in a phase 1 clinical trial in healthy volunteers. In addition, Chinook is advancing research programs for other rare, severe chronic kidney diseases. Chinook is building its pipeline by leveraging insights in kidney single cell RNA sequencing, human-derived organoids and new translational models, to discover and develop therapeutics with differentiating mechanisms of action against key kidney disease pathways. To learn more, visit www.chinooktx.com.
